EPCAM and metabolic dysfunction-associated steatohepatitis: In conclusion, we demonstrated that the NASH liver microenvironment promotes EpCAM+ CSC-mediated HCC tumor initiation in an immunocompetent mouse model, thus recapitulating clinical conditions.